ClinicalTrials.gg
CompletedNCT01156077Updated Dec 7, 2018

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

A Phase 1 interventional study of TR-701 FA and TR-701 FA in Bacterial Infection, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Bacterial Infections by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Merck & Co., Inc.

Enrollment
11th of 12
20 · median 83
Started
2010
with 1 other
Phase 1
3 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Bacterial Infections by Merck & Co., Inc, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 3 in phase 1, and was the 8th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 12 studies in Bacterial Infections by Merck & Co., Inc is open now. The open studies under Bacterial Infections, anywhere →

Where they have run

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Bacterial Infections by Merck & Co., Inc as a file.
02

Study summary

This is an open-label, multi-center, two-part, parallel-design study to assess the PK, safety, and tolerability of TR-701 FA and its active metabolite, TR-700, following a single oral dose (Part A) or IV dose (Part B) of TR-701 FA in 12 to 17 year old adolescent patients.

03

Conditions studied

  • Bacterial Infection

Browse trials for

Keywords

  • antibiotic
  • Adolescents receiving antibiotics
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • males and females, between 12 and 17 years of age, inclusive;
  • receiving prophylaxis for or have a confirmed or suspected infection with Gram positive bacteria and receiving concurrent antibiotic treatment with Gram positive antibacterial activity
  • in stable condition
  • females must be premenarchal, surgically sterile, abstinent, or practicing an effective method of
  • males will either be surgically sterile, abstinent, or practicing an effective method of birth control

Exclusion criteria

Exclusion Criteria:

  • relevant history of seizures, cardiac arrhythmia, cystic fibrosis, moderate or severe renal impairment, or any physical condition that could interfere with the interpretation of the study results
  • any acute or chronic condition that, in the opinion of the Investigator, would limit the patient's ability to complete and/or participate in this clinical study
  • physician-diagnosed migraine headaches
  • history of infection with hepatitis or other significant hepatic disease
  • females who are pregnant or breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    oral TR-701 FA

    Single oral dose of 200 mg TR-701

    Drug: TR-701 FA

  • Experimental
    IV TR-701 FA

    Single IV infusion of 200 mg TR-701 FA

    Drug: TR-701 FA

Interventions

  • Oral TR-701 FA 200 mg will be given as a single oral dose

  • TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline

06

What researchers measure

Primary outcomes

  1. Adolescent PK

    To describe the single-dose pharmacokinetics (PK) of IV and oral TR-701 FA administration in 12 to 17 year old adolescent patients, based on the individual plasma and urine concentration-time data.

    Time frame: 2 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bradley JS, Flanagan SD, Arrieta AC, Jacobs R, Capparelli E, Prokocimer P. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents. Pediatr Infect Dis J. 2016 Jun;35(6):628-33. doi: 10.1097/INF.0000000000001096. PubMed 26910588 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Sep 2011, 15 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 15 months is above that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2010
First posted
Jul 2, 2010
StartActual
Jun 2, 2010
Primary completionActual
Sep 24, 2011
CompletionActual
Sep 24, 2011
Last update
Dec 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01156077
Responsible party
Sponsor
First posted
Jul 2, 2010
Start date
Jun 2, 2010
Primary completion
Sep 24, 2011
Completion
Sep 24, 2011
Last update
Dec 7, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion